|
1
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
American Cancer Society. Cancer facts and
figures 2010. Atlanta: American Cancer Society; 2010
|
|
3
|
Zugazagoitia J, Manzano A, Sastre J,
Ladero JM, Puente J and Dìaz-Rubio E: Sorafenib for non-selected
patient population with advanced hepatocellular carcinoma: efficacy
and safety data according to liver function. Clin Transl Oncol.
15:146–153. 2013. View Article : Google Scholar
|
|
4
|
Bruix J and Sherman M; Practice Guidelines
Committee, American Association for the Study of Liver Diseases.
Management of hepatocellular carcinoma. Hepatology. 42:1208–1236.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bruix J, Sherman M, Llovet JM, et al; EASL
Panel of Experts on HCC. Clinical management of hepatocellular
carcinoma. Conclusions of the Barcelona-2000 EASL Conference.
European Association for the Study of the Liver. J Hepatol.
35:421–430. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wilhelm SM, Carter C, Tang L, et al: BAY
43–9006 exhibits broad spectrum oral antitumor activity and targets
the RAF/MEK/ERK pathway and receptor tyrosine-kinases involved in
tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Villanueva A, Newell P, Chiang DY,
Friedman SL and Llovet JM: Genomics and signaling pathways in
hepatocellular carcinoma. Semin Liver Dis. 27:55–76. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kaneko S, Furuse J, Kudo M, et al:
Guideline on the use of new anticancer drugs for the treatment of
hepatocellular carcinoma 2010 update. Hepatology Res. 42:523–542.
2012. View Article : Google Scholar
|
|
9
|
Llovet JM, Ricci S, Mazzaferro V, et al;
SHARP Investigators Study Group. Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cheng AL, Kang YK, Chen Z, et al: Efficacy
and safety of sorafenib in patients in the Asia-Pacific region with
advanced hepatocellular carcinoma: a phase III randomized,
double-blind, placebo-controlled trial. Lancet Oncol. 10:25–34.
2009. View Article : Google Scholar
|
|
11
|
Kim BK, Kim SU, Park JY, et al:
Applicability of BCLC stage for prognostic stratification in
comparison with other staging systems: single centre experience
from long-term clinical outcomes of 1717 treatment-naïve patients
with hepatocellular carcinoma. Liver Int. 32:1120–1127. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wörns MA, Weinmann A, Pfingst K, et al:
Safety and efficacy of sorafenib in patients with advanced
hepatocellular carcinoma in consideration of concomitant stage of
liver cirrhosis. J Clin Gastroenterol. 43:489–495. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Peck-Radosavljevic M, Greten TF, Lammer J,
Rosmorduc O, Sangro B, Santoro A and Bolondi L: Consensus on the
current use of sorafenib for the treatment of hepatocellular
carcinoma. Eur J Gastroenterol Hepatol. 22:391–398. 2010.
View Article : Google Scholar
|
|
14
|
Abou-Alfa GK, Amadori D, Santoro A, et al:
Safety and efficacy of sorafenib in patients with hepatocellular
carcinoma (HCC) and Child-Pugh A versus B cirrhosis. Gastrointest
Cancer Res. 4:40–44. 2011.PubMed/NCBI
|
|
15
|
Miller AA, Murry DJ, Owzar K, et al: Phase
I and pharmacokinetic study of sorafenib in patients with hepatic
or renal dysfunction: CALGB 60301. J Clin Oncol. 27:1800–1805.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Abou-Alfa GK: Commentary: Sorafenib - the
end of a long journey in search of systemic therapy for
hepatocellular carci- noma, or the beginning? Oncologist. 14:92–94.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chiu J, Tang JF, Yao TJ, et al: The use of
single-agent sorafenib in the treatment of advanced hepatocellular
carcinoma patients with underlying Child-Pugh B liver cirrhosis: a
retrospective analysis of efficacy, safety, and survival benefits.
Cancer. 118:5293–5301. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Llovet JM, Brú C and Bruix J: Prognosis of
hepatocellular carcinoma: the BCLC staging classification. Semin
Liver Dis. 19:329–338. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tandon P and Garcia-Tsao G: Prognostic
indicators in hepatocellular carcinoma: a systematic review of 72
studies. Liver Int. 29:502–510. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim JE, Ryoo BY, Ryu MH, et al: Sorafenib
for hepatocellular carcinoma according to Child-Pugh class of liver
function. Cancer Chemother Pharmacol. 68:1285–1290. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hollebecque A, Cattan S, Romano O, et al:
Safety and efficacy of sorafenib in hepatocellular carcinoma: the
impact of the Child-Pugh score. Aliment Pharmacol Ther.
34:1193–1201. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pinter M, Sieghart W, Graziadei I, et al:
Sorafenib in unresectable hepatocellular carcinoma from mild to
advanced stage liver cirrhosis. Oncologist. 14:70–76. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Iavarone M, Cabibbo G, Piscaglia F, et al;
SOFIA (SOraFenib Italian Assessment) study group. Field-practice
study of sorafenib therapy for hepatocellular carcinoma: a
prospective multicenter study in Italy. Hepatology. 54:2055–2063.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Je Y, Schutz FA and Choueiri TK: Risk of
bleeding with vascular endothelial growth factor receptor
tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic
review and meta-analysis of clinical trials. Lancet Oncol.
10:967–974. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lencioni R, Kudo M, Ye SL, et al: GIDEON
(Global Investigation of therapeutic DEcisions in hepatocellular
carcinoma and Of its treatment with sorafeNib): second interim
analysis. Int J Clin Pract. 68:609–017. 2014. View Article : Google Scholar :
|
